Asta Literature Retrieval: Pathophysiology and clinical mechanisms of Spondylometaphyseal Dysplasia Kozlowski Type. Core disease mechanisms, mol...

This report is retrieval-only and is generated directly from Asta results.

• Papers retrieved: 17
• Snippets retrieved: 20

Relevant Papers

[1] Comparison of the natural course of clinical and radiologic features in 13 patients with TRPV4-related skeletal dysplasias

• Authors: N. Güneş, D. U. Alkaya, S. Kuruğoğlu, Nuri Özyalvaç, Aysegul Bursali et al.
• Year: 2025
• Venue: Pediatric Radiology
• URL: https://www.semanticscholar.org/paper/9fdd70dc2984ec62d40362c854829ed800df471a
• DOI: 10.1007/s00247-024-06145-7
• PMID: 39825918
• Citations: 1
• Summary: Comparison of radiologic features that change with age in five different TRPV4-related skeletal dysplasias will be of great benefit in the management of this patient group.
• Evidence snippets:
• Snippet 1 (score: 0.577) > Heterozygous TRPV4 mutations cause a group of skeletal dysplasias characterized by short stature, short trunk, and skeletal deformities. The aim of this study is to compare the natural history of clinical and radiologic features of patients with different TRPV4-related skeletal dysplasias. Thirteen patients with a mutation in TRPV4 were included in the study, and 11 were followed for a median of 6.5 years. The clinical phenotype of five patients was compatible with spondylometaphyseal dysplasia Kozlowski type, three each with metatropic dysplasia and brachyolmia type 3, and one each with spondyloepiphyseal dysplasia Maroteaux type and congenital distal spinal muscular atrophy. Short stature and bone pain when running, walking, and climbing stairs occurred in patients with spondylometaphyseal dysplasia Kozlowski type and metatropic dysplasia from the age of 5 years and worsened with increasing age. Kyphosis was more pronounced with increasing age in these two groups of patients, while severe scoliosis occurred in brachyolmia type 3. In the radiographs of patients with spondylometaphyseal dysplasia Kozlowski type and metatropic dysplasia, severe platyspondyly persisted into adulthood or puberty. The patients with spondylometaphyseal dysplasia Kozlowski type exhibited irregular proximal femora leading to destruction of the femoral head towards the end of puberty, whereas metatropic dysplasia showed marked irregularity and widening of the femoral neck. We also observed that metaphyseal dysplasia in long bones other than the proximal femur was so inconspicuous that it could be ignored in patients with spondylometaphyseal dysplasia Kozlowski type. Comparison of radiologic features that change with age in five different TRPV4-related skeletal dysplasias will be of great benefit in the management of this patient group.
• Snippet 2 (score: 0.435) > Five of the patients with spondylometaphyseal dysplasia Kozlowski type presented here had this recurrent p.Arg594His variant [16]. However, this variant was also observed in two cases with metatropic dysplasia and the patients with a phenotype between spondylometaphyseal dysplasia Kozlowski type and metatropic dysplasia [5,11]. Two of our patients with the metatropic dysplasia phenotype had the p.Pro799Arg and p.Pro799Leu variants in exon 15, which are mostly associated with the classic metatropic dysplasia phenotype [11]. These mutations have also been found in patients with the spondyloepiphyseal dysplasia Maroteaux type [6,13,17]. The p.Glu797Gly variant that occurred in our third patient has not yet been identified, but another substitution at the same residue (p.Glu797Lys) has been reported in several cases with mild metatropic dysplasia, spondylometaphyseal dysplasia Kozlowski type, and spondyloepiphyseal dysplasia Maroteaux type [8,11,13]. > It has been reported that the clinical and radiologic features of patients with classic metatropic dysplasia and spondylometaphyseal dysplasia Kozlowski type overlap considerably [3,5]. When we compared patients in early childhood, it was easy to distinguish clinically between patients with spondylometaphyseal dysplasia Kozlowski and metatropic dysplasia; the trunk was short in patients with Kozlowski type, whereas it was narrow and long in metatropic dysplasia, and the extremities were short with a prominent knee.
• Snippet 3 (score: 0.399) > In 1973, Kozlowski et al. [18] reported that patients with this dysplasia reached a final height of 130-150 cm. After this study, only one 33-year-old woman with spondylometaphyseal dysplasia Kozlowski type was reported who was 145 cm (−3 SDS) tall and complained of intermittent back pain but had no limitations in her activities of daily living [6]. The patients with spondylometaphyseal dysplasia Kozlowski type presented here gradually developed a barrel-shaped chest from late childhood to adulthood. In addition, they exhibited a swan-neck deformity of the fingers that became apparent during puberty, as in previous observations of patients with an intermediate phenotype [19]. > The main complications reported in a cohort of patients with classic metatropic dysplasia were a short thorax and progressive kyphoscoliosis, as well as pain and gait disturbances due to hip and knee contractures [12]. In one of our patients with metatropic dysplasia, whom we followed until the age of 10 years, the ratio of sitting height/height had decreased from 0.54 to 0.52. This patient, who we considered to have a mild form of metatropic dysplasia, had received preventive physiotherapy since the age of one, had not developed kyphoscoliosis and his height was not very short. It has been reported that in patients with the mild form of metatropic dysplasia, clinical findings begin in the neonatal period but progress slowly, and that body disproportion may be mild in the early stages, the trunk is initially long and narrow but may assume a barrel shape with age, kyphoscoliosis may be absent [5]. Follow-up of our two other patients with metatropic dysplasia revealed kyphosis at an early age, which is more severe than spondylometaphyseal dysplasia Kozlowski type with a forward bending gait, and pain on walking long distances and climbing stairs increases with age.

[2] Spondylometaphyseal dysplasia in a 2-year-old Sri Lankan girl

• Authors: Piyumi Madawala, Chanika Lokuhewage, Sudarshana Bandara, Shobhavi Randeny, S. Mettananda
• Year: 2024
• Venue: Sri Lanka Journal of Child Health
• URL: https://www.semanticscholar.org/paper/a72be9b7a3a0c6afb45a0a2517bdf2a291ccc39c
• DOI: 10.4038/sljch.v53i1.10804
• Summary: No abstract available
• Evidence snippets:
• Snippet 1 (score: 0.556) > Spondylo-metaphyseal dysplasia is characterized by metaphyseal dysplasia, generalized platyspondyly and radiographic changes in the spine, pelvis and proximal femur 1,5 .The child has classic features of spondylometaphyseal dysplasia that include short stature, short neck, pectus carinatum, varus deformity of limbs, and waddling gait 6 .Dorsal kyphoscoliosis, also a classic feature, is expected to develop during adolescence.Diagnostic radiographic findings in our case were generalized platyspondyly with anteriorly rounded/wedged vertebral bodies, widening, sclerosis and irregularity of metaphysis and carpal ossification delay 6,7 . > Kozlowski classified spondylo-metaphyseal dysplasia into seven types based on severity, individual bones involved and transmission pattern 1 .Clinical features of our patient resemble spondylo-metaphyseal dysplasia type 1 -Kozlowski type; however, definitive diagnosis can only be made following molecular genetic studies.The differential diagnoses of type 1 include Kniest dysplasia, Jansen type metaphyseal chondrodysplasia, spondyloepiphyseal dysplasia, metatropic dysplasia and Morquio disease.All these diseases exhibit vertebral and metaphyseal abnormalities; however, they also have other features or organ anomalies that were not present in our patient 8,9 .Morquio disease was excluded in our patient by a negative urine test for mucopolysaccharidosis. > Spondylo-metaphyseal dysplasia does not have a cure.The treatment is targeted at symptomatic therapy, support, and counselling.Potential late complications include kyphoscoliosis and cervical spine instability due to odontoid hypoplasia 6 .Screening x-rays of the cervical and thoracolumbar spine and neck are recommended 2-3 yearly to monitor for cervical spine instability, kyphosis and scoliosis 2 .

[3] Metatropic Dysplasia: A Description of a Newborn With Suspected Epiphyseal Dysplasia

• Authors: Agnieszka Byrwa, I. Michałus, Paulina Adamiecka, E. Jakubowska-Pietkiewicz
• Year: 2019
• Venue: Journal of Endocrinology and Metabolism
• URL: https://www.semanticscholar.org/paper/6d6c2d29d53bd566c1f77fe6912d7c381686cd88
• DOI: 10.14740/jem598
• Summary: A female neonate with a suspected skeletal defect that was eventually diagnosed as metatropic dysplasia was presented, and in the collected genetic material no TRPV4 mutation was discovered.
• Evidence snippets:
• Snippet 1 (score: 0.546) > It is characterised by short limbs, [6,7]. Our infant had no flattened femurs described for type I TD, nor flat femurs present in type II TD, no cloverleaf skull deformity was stated, so this syndrome was excluded as a diagnosis. Spondylometaphyseal dysplasia, Kozlowski type, is a relatively common autosomal dominant disease in a heterogeneous group of approximately 30 different disorders with vertebral and tabular bone metaphyses abnormalities. It is one of the best clinically defined spondylometaphyseal dysplasias with molecular basis explained. TRPV4 mutations identified in patients with this disorder affect calcium-permeable ion channels. These mutations of bone dysplasias are characterised by dwarfism, kyphoscoliosis, distortion and bowing of the extremities, and contractures of the large joints. This disease is characterised by a combination of decreased bone density, bowing of the long bones, platyspondyly and irregularities of endochondral ossification with areas of calcification and streaking in epiphyses, metaphyses and apophyses [8,9]. The observed neonate had no TRPV4 gene mutation, long bones had "mushroom-like" epiphyses, however without bowing, moreover no streaking in the epiphyses was described, therefore this syndrome was also excluded as a diagnosis. > In the described case the respiration was maintained using SIMV, which enabled to discharge the child to continue treatment at the hospital at her place of residence. Also monitoring of biochemical and calcium-phosphorus metabolism assessing parameters is important to supply adequate doses of vitamin D3 or possibly calcium. A significant issue that we wish to emphasize is the possibility to perform corrective surgeries to stop malformation progression; however it depends on the moment of such an intervention as well as on the careful selection of patients, especially the assessment of pulmonary function. It seems that in the case presented in the paper there will not be such an opportunity, and bone deformities will progress, and probably increase respiratory disorders.

[4] TRPing to the Point of Clarity: Understanding the Function of the Complex TRPV4 Ion Channel

• Authors: T. Toft-Bertelsen, N. MacAulay
• Year: 2021
• Venue: Cells
• URL: https://www.semanticscholar.org/paper/62a3488c04cb9d2974e59b91aa0740ac87aab0cc
• DOI: 10.3390/cells10010165
• PMID: 33467654
• PMCID: 7830798
• Citations: 44
• Influential citations: 1
• Summary: This review will highlight structural features of TRPV4, endogenous and exogenous activators of the channel, and discuss the reported roles of TRpV4 in health and disease.
• Evidence snippets:
• Snippet 1 (score: 0.486) > Generally, there are no fundamental differences in the positions and/or patterns of amino acid substitutions within the two disease spectrums [4]. It is noticeable that TRPV4 channelopathies display a striking phenotypic variability, despite the disease-causing mutations being located in the same channel domains. While this variability is readily observed within the groups of mutations causing neuropathies and skeletal dysplasias, a few specific mutations (localized to N and C termini and the TM5) can give rise to phenotypes falling within either of the disease categories-or a combination thereof [131]: A217S: Spondylometaphyseal dysplasia Kozlowski and Scapuloperoneal spinal muscular atrophy. > E278K: Spondylometaphyseal dysplasia Kozlowski/Metatropic dysplasia and Scapuloperoneal spinal muscular atrophy. > V620I: Autosomal dominant brachyolmia type 3 and Scapuloperoneal spinal muscular atrophy. > P799R: Spondylo-epimetaphyseal dysplasia Maroteaux pseudo-Morquio type/Parastremmatic dwarfism and Charcot-Marie-Tooth disease type 2C. > This overlapping genotype-phenotype relation suggests that the underlying pathogenic mechanisms of skeletal and nerve TRPV4 channelopathies are not always mutually exclusive. > The relatively mild phenotype of the trpv4 -/-mice and the lack of obvious undesirable side-effects of systemically delivered TRPV4 inhibitors to mice and rats [101] suggest that gain-of-function mutations in TRPV4 underlie the majority of the disabling, or even lethal, human diseases. Whether it is a matter of compensatory mechanisms occurring with potential loss-of-function mutations or solely gain-of-function mutations causing disease, the severe pathologies observed with mutations in the trpv4 gene underscore the vital role that TRPV4 function plays in regulation of diverse cellular processes.

[5] A novel TRPV4 variant in spondylometaphyseal dysplasia, kozlowski type reveals a previously unreported loss-of-function mechanism

• Authors: Han Wang, Shuang Li, Yiming Xu, Bin Feng, Xiuli Zhao et al.
• Year: 2025
• Venue: Orphanet Journal of Rare Diseases
• URL: https://www.semanticscholar.org/paper/0349ab15b5f7918a0693883dbfe12e698f6c2708
• DOI: 10.1186/s13023-025-04070-y
• PMID: 41225599
• PMCID: 12613735
• Summary: These findings establish p.W785S as a novel pathogenic variant and highlight loss of TRPV4 activity as an alternative mechanism contributing to disease pathogenesis in SMDK.
• Evidence snippets:
• Snippet 1 (score: 0.477) > Spondylometaphyseal Dysplasia, Kozlowski Type (SMDK) is an autosomal dominant skeletal disorder characterized by marked scoliosis, platyspondyly, overfaced pedicles, and mild metaphyseal changes. Pathogenic variants in TRPV4, which encodes a calcium-permeable nonselective cation channel, are known to underlie SMDK. In this study, we identified a previously unreported missense variant in NM_021625.5(TRPV4): c.2354G > C (p.Trp785Ser), in a patient clinically diagnosed with SMDK. This variant affects a highly conserved residue and is predicted to alter protein conformation. Functional validation through cellular experiments revealed that the p.W785S substitution markedly reduces agonist-induced calcium influx and membrane currents, indicating a loss-of-function effect on TRPV4 channel activity. This deviates from the typical gain-of-function paradigm observed in most TRPV4-related skeletal dysplasias and may explain the relatively milder phenotype in our case. Our findings establish p.W785S as a novel pathogenic variant and highlight loss of TRPV4 activity as an alternative mechanism contributing to disease pathogenesis in SMDK.

[6] Metatropic Dysplasia of Nonlethal Variant in a Chinese Child – A Case Report

• Authors: Michele A Tchio Tchoumba, Yan Bai, R. Jin, Xian-Mei Yu, M. Male
• Year: 2019
• Venue: Orthopaedic Surgery
• URL: https://www.semanticscholar.org/paper/f972f9e2d0001fc1424a23345612aa61c7d211a3
• DOI: 10.1111/os.12546
• PMID: 31808622
• PMCID: 7031589
• Citations: 3
• Summary: A case of a 14‐month old girl who presented with an abnormal stature is reported, recorded with metatropic dysplasia with the c.2396C > T mutation in the TRPV4 gene in China.
• Evidence snippets:
• Snippet 1 (score: 0.460) > M D is a type of dysplasia by dwarfism. It is classified among various forms of skeletal dysplasias caused by TRPV4 gene impairment which incorporates familial digital arthropathy-brachydactyly, autosomal dominant brachyolmia, spondylometaphyseal dysplasia-Kozlowski type (SMDK), spondyloepiphyseal dysplasia-Maroteaux type (SEDM), parastremmatic dysplasia, and finally metatropic dysplasia 3,5 . MD accounts for 5% of cases identified by the International Skeletal Dysplasia Registry 6 . > MD was first reported in 1893 as an atypical chondrodysplasia marked by short limbs, widened joints, and severe kyphoscoliosis 6 . Despite the appearance of several features associated with the disorder, some major phenotypes associated with this disorder are severe platyspondyly, shortened long bones, and dumbbell metaphyses 7 . MD appears to have a series of variants which include: (i) lethal form with distinct characteristics of semicircular iliac bones, shortened distance between successive pedicles, short diced ribs, underdeveloped chest, short voluminous pedicles, and long bones with extended mushroom metaphyses 8 ; (ii) nonlethal dominant form characterized by progressive scoliosis, bone metaphyseal involvement, and delayed carpal ossification 1 ; and (iii) nonlethal with autosomal recessive transmission 9 . Lethal forms are usually detected in the perinatal period through ultrasound and can be differentiated from the other forms via judge of phenotype severity and increment of mortality 10 . Nonlethal forms, on the other hand, present in childhood with short stature, failure of linear growth, or other physical abnormalities 4 . Widened metaphyses leading to dumbbell appearance, small epiphyses, platyspondyly, and distinctive pelvic shape with flared ilia and horizontal acetabula are the radiological diagnostic criteria of MD 11 . However, the precise diagnosis is obstructed by the low efficiency of handling the complications and genetic counseling 4 .

[7] EndoCompass Project: Research Roadmap for Calcium and Bone Endocrinology

• Authors: K. Jähn-Rickert, K. Z. Tomsic, A. Anastasilakis, Jean-Philippe Bertocchio, M. L. Brandi et al.
• Year: 2025
• Venue: Hormone Research in Pædiatrics
• URL: https://www.semanticscholar.org/paper/fccbdcae3a86c448632e05f9c38ad2563c14284d
• DOI: 10.1159/000549160
• PMID: 41296665
• PMCID: 12698132
• Summary: This framework identifies crucial investigation areas into metabolic bone disease pathophysiology, prevention, and treatment strategies, ultimately aimed at reducing the burden of these disorders on individuals and society.
• Evidence snippets:
• Snippet 1 (score: 0.435) > Skeletal dysplasias encompass a large spectrum of genetic disorders of the skeleton with abnormal bone growth, structure, or strength [85]. Individually, they are rare but, collectively, due to the large number of skeletal dysplasias (>700), they result in significant morbidity. The underlying pathology remains inadequately understood and the optimal therapy is often undefined, with precision drug treatment targeting the underlying molecular mechanism not available for most skeletal dysplasias. Gene discoveries have increased exponentially, demonstrating the value of advanced genetic tools and motivating further research into the complex pathogenesis of skeletal dysplasias. > However, further basic research is required to uncover the cellular pathology and implicated molecular pathways in various forms of skeletal dysplasia. Understanding the pathophysiology of skeletal dysplasias may also benefit a larger patient population. This is evidenced by anti-sclerostin treatment for osteoporosis [86] which, at present, is in clinical trials for osteogenesis imperfecta. Preclinical data show positive effects on bone mass and strength [87]. > The spectrum of disease manifestations of various skeletal dysplasias in different phases of life and health projections across the life course remain inadequately studied. Research on therapeutic approaches needs to focus not only on correcting the pathophysiology but also, more broadly, on surgical approaches, rehabilitation, functional/environmental adaptations, preventative measures, pain management, psychological support, and quality of life. Patient groups must be involved in identifying these research goals. International registries should be utilized to collect and analyse such data. > A multidisciplinary approach is of particular importance in genetic skeletal disorders, to enable cohesive care throughout the life course. The patients have a range of physical impairments due to their skeletal disorder, but also a disease-specific spectrum of extraskeletal manifestations requiring medical attention. These may include, for example, dental and oral health problems, immune deficiency, impaired hearing, and neurological or ophthalmologic manifestations.

[8] Cartilage Oligomeric Matrix Protein Interacts with Type IX Collagen, and Disruptions to These Interactions Identify a Pathogenetic Mechanism in a Bone Dysplasia Family*

• Authors: P. Holden, R. S. Meadows, K. Chapman, M. E. Grant, K. Kadler et al.
• Year: 2001
• Venue: The Journal of Biological Chemistry
• URL: https://www.semanticscholar.org/paper/046e8b3d3535533eac1b21ecd692766cb0f5c88a
• DOI: 10.1074/JBC.M009507200
• PMID: 11087755
• Citations: 215
• Influential citations: 13
• Summary: Analysis of COMP-type IX collagen complexes demonstrated that COMP interacts with type IX collagen through the noncollagenous domains of type VIII collagen and the C-terminal domain of COMP, and peptide mapping identified a putative collagen-binding site that is associated with known human mutations.
• Evidence snippets:
• Snippet 1 (score: 0.431) > Cartilage oligomeric matrix protein (COMP) and type IX collagen are key structural components of the cartilage extracellular matrix and have important roles in tissue development and homeostasis. Mutations in the genes encoding these glycoproteins result in two related human bone dysplasias, pseudoachondroplasia and multiple epiphyseal dysplasia, which together comprise a "bone dysplasia family." It has been proposed that these diseases have a similar pathophysiology, which is highlighted by the fact that mutations in either the COMP or the type IX collagen genes produce multiple epiphyseal dysplasia, suggesting that their gene products interact. To investigate the interactions between COMP and type IX collagen, we have used rotary shadowing electron microscopy and real time biomolecular (BIAcore) analysis. Analysis of COMP-type IX collagen complexes demonstrated that COMP interacts with type IX collagen through the noncollagenous domains of type IX collagen and the C-terminal domain of COMP. Furthermore, peptide mapping identified a putative collagen-binding site that is associated with known human mutations. These data provide evidence that disruptions to COMP-type IX collagen interactions define a pathogenetic mechanism in a bone dysplasia family. > The skeletal dysplasias are a diverse group of genetic diseases affecting primarily the development of the osseous skeleton, and range in severity from relatively mild to severe and lethal forms (1). There are over 200 unique well characterized phenotypes (2), and many of these conditions have been grouped into "bone dysplasia families" on the basis of similar clinical and radiographic presentation with the supposition that they will share a common disease pathophysiology (3). While there has been great progress in identifying many of the genes involved in these diseases (4,5), we still have a very limited understanding of the precise cell matrix pathology of individual phenotypes and the relationship between pathogenetic mechanisms within specific bone dysplasia families.

[9] A new form or a variant of SMD type A4

• Authors: I. Marik, O. Hudakova, S. Petrasova, Lukasz Kuszel, M. Czarny‐Ratajczak et al.
• Year: 2012
• Venue: Journal of Applied Genetics
• URL: https://www.semanticscholar.org/paper/56835a497c2a60be0321d5910de50c4442177a42
• DOI: 10.1007/s13353-012-0094-0
• PMID: 22528043
• PMCID: 3402664
• Citations: 1
• Summary: In addition to classical SMDTA4 characteristics, the patient has progressive scoliosis and lack of ossification of the capital femoral epiphyses at the age of 11 years, and the PTHR1 gene encoding PTH/PTHrP receptor for parathyroid hormone related peptide (PTHRP) and parathy thyroid hormone (PthrP) is analyzed.
• Evidence snippets:
• Snippet 1 (score: 0.429) > All other publications on SMD (Czarny-Ratajczak et al. 2009;Dieux-Coeslier et al. 2004;Goldblatt et al. 1991;Gustavson et al. 1978;Kozlowski et al. 1988;Kozlowski et al. 1976;Peeden et al. 1992;Shebib et al. 1991;Walters et al. 2004), characterize patients with phenotypes other than that of our patient, and a different pattern and severity of radiographic changes. The variety of SMD forms is most likely the consequence of mutations in different genes that are involved in cartilage development. Spondylometaphyseal dysplasias as well as spondyloepimetaphyseal dysplasias are very heterogeneous groups of bone dysplasias still explored at the molecular level, which in familial cases, frequently leads to identification of new candidate genes for these disorders. The unknown molecular background of SMDTA4 and lack of affected family members significantly limits the diagnostic options for sporadic patients with rare forms of SMD.

[10] WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders

• Authors: Yentl Huybrechts, G. Mortier, E. Boudin, W. Van Hul
• Year: 2020
• Venue: Frontiers in Endocrinology
• URL: https://www.semanticscholar.org/paper/00fd0aa090f258a34c6590bc3dee4b211ecb0929
• DOI: 10.3389/fendo.2020.00165
• PMID: 32328030
• PMCID: 7160326
• Citations: 95
• Summary: This review discusses the skeletal disorders that are included in the latest nosology of skeletal disorders and that are caused by genetic defects involving the Wingless and int-1 (WNT) signaling pathway.
• Evidence snippets:
• Snippet 1 (score: 0.423) > The identification of novel disease-causing genes for rare skeletal dysplasias accelerated significantly in the last decades, initially by positional cloning efforts and more recently by the availability of next-generation sequencing technology. This resulted in the identification of the disease-causing gene for 92% of the skeletal disorders (6). The increased knowledge on monogenic diseases resulted in a better understanding of the pathological mechanisms and highlighted which pathways regulate specific cellular processes. This information is also relevant for understanding more common multifactorial diseases. Furthermore, it has been shown that therapeutic targets which are based on genetic evidence from Mendelian traits as well as genome-wide association studies (GWASs) are more likely to be successful in clinical studies for multifactorial diseases (150). Here, we focused on skeletal dysplasias caused by mutations in genes that encode proteins that are directly involved in one of the WNT signaling pathways. As shown in Table 1, mutations in these genes can result in a variety of skeletal dysplasias, each with specific clinical features. The broad spectrum of clinical observations reflect the cellular and spatial functions of WNT signaling, some of them associated with embryonal development, others with bone mass and homeostasis in adult life. For example, the clinical features of RS and OMOD are similar which led to the hypothesis that all causative genes are involved in the WNT/PCP pathway which is previously shown to be important during limb development (Figure 2) (102). On the other hand, the influence of canonical WNT signaling on bone mass was highlighted by unraveling the underlying pathogenic mechanisms of disorders with a progressively increasing bone mass such as sclerosteosis, Van Buchem disease, and high bone mass phenotypes (osteosclerosis) (51,53,57,107,113). The genes causing these disorders, SOST, LRP4, LRP5, and LRP6, are all involved in the canonical WNT signaling pathway (Figure 3), and all mutations reported result in an increased canonical WNT signaling (Table 1).

[11] New therapeutic targets in rare genetic skeletal diseases

• Authors: M. Briggs, Peter A. Bell, M. Wright, K. A. Pirog
• Year: 2015
• Venue: Expert Opinion on Orphan Drugs
• URL: https://www.semanticscholar.org/paper/1363107f71ae6d2d60abca471cddf3da5d13644b
• DOI: 10.1517/21678707.2015.1083853
• PMID: 26635999
• PMCID: 4643203
• Citations: 37
• Influential citations: 1
• Summary: An overview of disease mechanisms that are shared amongst groups of different GSDs and potential therapeutic approaches that are under investigation are described to generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.
• Evidence snippets:
• Snippet 1 (score: 0.420) > Several studies have recently demonstrated that reduced chondrocyte proliferation, increased and/or dysregulated apoptosis in the growth plates of mouse models is a major pathological component of various GSDs, including those resulting from mutations in genes encoding cartilage structural proteins (Comp, Matn3 and Col2a1) [8,12,104], a sulphate transporter (Slc26a2) [105] and components of the trans-golgi network (GMAP-210) [32]. These pathomolecular mechanisms are particularly relevant to those GSDs that have a significant epiphyseal involvement, such as PSACH-MED, DTDST and the type II collagenopathies, but are perhaps not so relevant for metaphyseal chondrodysplasias such at MCDS where the pathology involves only non-proliferating hypertrophic chondrocytes [16]. [87,88] AD: Autosomal dominant; AR: Autosomal recessive; BMP: Bone morphogenetic protein; GSDs: Genetic skeletal diseases; SMD: Spondylometaphyseal dysplasia. > Defining the relative contribution of reduced chondrocyte proliferation, increased and/or dysregulated apoptosis to growth plate dysplasia and reduced bone growth is experimentally challenging; however, the study of novel 'ER-stress phenocopies' has recently provided new insight into the specific impact of these different disease mechanisms [16,106,107]. The cartilage-specific expression of mutant forms of thyroglobulin has confirmed that reduced chondrocyte proliferation resulting from an intracellular stress caused by the accumulation of a misfolded protein and in the absence of perturbations to apoptosis was sufficient to cause a significant reduction in long bone growth [107]. > In summary, these innovative studies therefore defined reduced chondrocyte proliferation as a major determinant of reduced bone growth in epiphyseal dysplasias, which holds the promise of therapeutic intervention or as a robust readout of drug efficacy in these pre-clinical models of GSDs.
• Snippet 2 (score: 0.408) > proteins of the cartilage ECM such as type II collagen [50]. However, emerging knowledge suggests that the primary genetic defect may be less important than the cells' response to the expression of the mutant gene product [107]. Moreover, the largely overlooked response of a cell (i.e. chondrocyte) to the abnormal extracellular environment is also important for disease progression as illustrated by several GSDs discussed in this review. > It is important that 'omics'-based approaches and technologies are systematically applied to the study of rare GSDs so that definitive reference profiles and disease signatures are generated for each phenotype. These can then be used in a Systems Biology approach to identify both common and dissimilar pathological signatures and disease mechanisms. This approach is entirely dependent upon relevant in vitro and in vivo models (and also novel 'disease-mechanism phenocopies' [107]) for testing new diagnostic and prognostic tools and for determining the molecular mechanisms that underpin the pathophysiology so that effective therapeutic treatments can be developed and validated. This approach will eventually lead to personalized treatments and care strategies centred on shared disease mechanisms with the use of relevant biomarkers to monitor the efficacy of treatment and disease progression. > It is vital that all relevant stakeholders are involved from the outset in defining the appropriate outcomes of any potential therapeutic regime. The perceptions of a successful therapy can differ widely between the clinical academic community and the relevant patient-support groups and it is vital that there is engagement on all these issues. > In summary, the identification of causative genes and mutations for GSDs over the last 20 years, coupled with the generation and in-depth analysis of a plethora of relevant cell and mouse models, has derived new knowledge on disease mechanisms and suggested potential therapeutic targets. The fast-evolving hypothesis that clinically disparate diseases can share common disease mechanisms is a powerful concept that will generate critical mass for the identification and validation of novel therapeutic targets and biomarkers.

[12] TRPV4: A Physio and Pathophysiologically Significant Ion Channel

• Authors: T. Rosenbaum, Miguel Benítez-Angeles, Raúl Sánchez-Hernández, S. Morales-Lázaro, M. Hiriart et al.
• Year: 2020
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/09943959f11255605b780fc692ef57a0cc9ef945
• DOI: 10.3390/ijms21113837
• PMID: 32481620
• PMCID: 7312103
• Citations: 105
• Influential citations: 3
• Summary: Several lines of evidence derived from animal models and even clinical trials in humans highlight TRPV4 as a therapeutic target and as a protein that will receive even more attention in the near future, as will be reviewed here.
• Evidence snippets:
• Snippet 1 (score: 0.418) > Certain diseases were previously thought to be distinct clinical phenotypes until it was discovered that there was a common underlying molecular basis: their association with the mutations and malfunction of TRPV4 (Figure 5). Presently, these disorders have been grouped into skeletal dysplasias (metatropic dysplasia, parastremmatic dysplasia, Maroteaux type spondyloepiphyseal dysplasia, Kozlowski type spondyloepiphyseal dysplasia (SMDK), autosomal dominant brachyolmia, familial digital arthropathy-brachydactyly), and into neuromuscular disorders (congenital distal spinal muscular atrophy, scapuloperoneal spinal muscular atrophy, Charcot-Marie-Tooth disease type 2C), which vary in severity. Skeletal dysplasias exhibit brachydactyly (shortness of fingers and toes), and depending on the severity of the disease, there is also short stature and spinal deformity, the pelvis, and long bones, which can also be affected, and sometimes the life span of the individuals is reduced. On the other hand, neuromuscular disorders present themselves with respiratory dysfunction, joint contractures, and progressive peripheral neuropathy [182]. > All of these diseases, which are grouped into two large categories (i.e., neuromuscular disease and skeletal dysplasia), encompass progressive degeneration of peripheral nerves or lack of establishment and development of the hard-skeletal tissues. > It had been previously shown that inactivation missense mutations in the PkdI (polycystic kidney disease) gene that encodes the polycystin-1 (PC1) membrane protein led to tardy intramembranous and endochondral bone formation in a mutant mice (Pkd1 mlBei ) strain [183]. A link between this discovery and the role of TRPV4 in the skeletal system was later made since it had been shown that PC1 activates TRPV4 through a G-protein coupled receptor (GPCR) mechanism [184].

[13] Non-Invasive Prenatal Screening for Down Syndrome: A Review of Mass-Spectrometry-Based Approaches

• Authors: Răzvan Lucian Jurca, I. Pralea, M. Iacobescu, I. Rus, C. Iuga et al.
• Year: 2025
• Venue: Life
• URL: https://www.semanticscholar.org/paper/77585fbeddaee796b0d9030dfccee9713f2d3e52
• DOI: 10.3390/life15050695
• PMID: 40430124
• PMCID: 12112985
• Citations: 1
• Summary: A comprehensive examination of the differentially expressed proteins (DEPs) and metabolites (DEMs) reported in the literature in T21 prenatal screening aims to guide future research in the field and foster the development of more advanced, less invasive prenatal screening techniques for T21.
• Evidence snippets:
• Snippet 1 (score: 0.413) > Additionally, CS and DS are commonly associated with atherosclerosis, nerve development and repair, inflammation, tumor growth, and metastasis [80]. Modifications of the enzymes involved in the biosynthesis of glycosaminoglycans are important in Ehlers-Danlos syndrome, joint dislocations, short stature, spondyloepiphyseal dysplasia with congenital joint dislocations, spondyloepimetaphyseal dysplasia with joint laxity type 1, congenital heart defects, and Temtamy preaxial brachydactyly syndrome. While congenital heart defects and joint laxity are common in T21 patients, the co-occurrence of T21 and Ehlers-Danlos syndrome is rare, and no established correlation exists between the two conditions [104]. > Pathways associated with diseases of hemostasis were predominantly observed in maternal plasma, along with pathways related to signal transduction mediated by growth factors and second messengers-specifically, oncogenic MAPK signaling. MAPKs are protein kinases that control intracellular processes, such as gene expression, metabolism, proliferation, differentiation, and apoptosis, as part of normal physiology, being mainly studied in the context of oncogenesis, tumor progression, and drug resistance [105]. MAPK pathways in T21 patients have been primarily studied to enhance antitumor treatment efficacy in patients with B cell acute lymphoblastic leukemia [106] or to assess MAPK activity in the brains of T21 and Alzheimer's disease patients [107]. > Table 2 summarizes the key molecular pathways implicated in Down syndrome (T21), emphasizing their normal biological functions and the observed or potential alterations in T21. While direct evidence for some pathways remains limited, numerous pathways-particularly those involved in signaling, immune functions, extracellular matrix organization, and metabolic processes-show promising associations with the clinical features of T21. Regarding the metabolomic pathways of significant differentially expressed metabolites (DEMs) in T21, brief discussions on this topic are included in the description of each metabolomic study outlined in the previous section.

[14] Skeletal Dysplasias Caused by Sulfation Defects

• Authors: Chiara Paganini, Chiara Gramegna Tota, A. Superti-Furga, A. Rossi
• Year: 2020
• Venue: International Journal of Molecular Sciences
• URL: https://www.semanticscholar.org/paper/e455f358a08f6e9fc09ef5f2d3751d11e9145e92
• DOI: 10.3390/ijms21082710
• PMID: 32295296
• PMCID: 7216085
• Citations: 25
• Influential citations: 1
• Summary: A panoramic view of skeletal dysplasias caused by mutations in genes encoding for transporters or enzymes involved in macromolecular sulfation is presented, allowing the development of targeted therapies aimed at alleviating, preventing, or modifying the disease progression.
• Evidence snippets:
• Snippet 1 (score: 0.410) > Over the last few years, there have been significant advances in the skeletal dysplasia field leading to the identification of the underlying genetic defects in more than 400 different skeletal disorders [15]. The above synopsis highlights the complexity of skeletal defects caused by mutations in genes encoding for enzymes and transporters involved in sulfate metabolism. Progress in this field has been allowed by next-generation genomic technologies, that are a first-line diagnostic resource. In this complex scenario, patient derived biopsies, cell cultures, and animal models are fundamental to investigate the pathogenesis and to analyze new aspects of the role of GAG in connective tissue biology. > Despite the great step forward in the identification of causative genes, genotype-phenotype correlations are lacking and we are still far from a comprehensive view of the disease molecular mechanisms. First, it is unclear how the tissue specificity and the redundancy of genes can determine the phenotype. Defects in PG sulfation mainly affect cartilage and bone, but other tissues can be involved as cardiac tissue in SEDCJD [82,84] or lymphoid tissue leading to tumour progression in OCBMD [91]. The involvement of different tissues and its implications on the disease phenotype should be carefully studied in the future. Moreover, mutations in different genes cause skeletal dysplasias with overlapping features that may be wrongly diagnosed as occurs in condrodysplasia with joint dislocation, gPAPP type, Catel-Manzke syndrome and Desbuquois dysplasia type 1. Nowadays we cannot provide a full explanation why some classes of sulfated PGs are more affected by enzyme deficiency than others. Even if the GAGs role depends on their physicochemical properties, it is difficult to molecularly dissect the function of sulfated GAGs when they interact in the complex ECM network. Lastly, the variability in the clinical phenotypes caused by mutations in the same gene suggests that also environmental and epigenetic factors might play a role. > A deep understanding of the molecular mechanisms of these disorders is crucial to ultimately pave the way for innovative therapies.

[15] SGMS1 facilitates osteogenic differentiation of MSCs and strengthens osteogenesis-angiogenesis coupling by modulating Cer/PP2A/Akt pathway

• Authors: Kai Yang, Ying-yi Luan, Shan Wang, You-sheng Yan, Yi-peng Wang et al.
• Year: 2024
• Venue: iScience
• URL: https://www.semanticscholar.org/paper/e7e06d8990bd8da5915a99e67961147679ac7323
• DOI: 10.1016/j.isci.2024.109358
• PMID: 38544565
• PMCID: 10966191
• Citations: 6
• Summary: SGMS1 induces osteogenic differentiation of MSCs and osteogenic-angiogenic coupling through the regulation of the Cer/PP2A/Akt signaling pathway through the regulation of the Cer/PP2A/Akt signaling pathway.
• Evidence snippets:
• Snippet 1 (score: 0.404) > Skeletal dysplasia (SD) refers to a group of diseases characterized by abnormal bone formation owing to intrinsic disorders in bone growth, development, and/or differentiation. 1 The overall prevalence of SD is at least one case per 1,000 births. 2 The clinical manifestations of SD vary, involving abnormalities in growth, bone density, or bone morphology, reflecting complex etiological mechanisms. Treatment options for SD are limited. In the past few decades, >400 genes that can cause SD have been discovered to better understand the cellular and biological pathways involved in skeletal development, 3 particularly congenital defects involving key regulators of bone formation in mesenchymal stem cells (MSCs) that may lead to rare genetic disorders of the bone. 4 MSCs have attracted much attention in recent years owing to their ability to induce osteogenic differentiation and secrete growth factors. 5 Osteogenic differentiation of MSCs is a complex, multistage process essential for normal bone formation, and this process is affected by multiple endogenous and environmental elements as well as multiple signaling pathways. 6 Elucidating the mechanism of regulating MSC osteogenic differentiation may aid in the development of novel therapies for the clinical treatment of SD or other diseases involving bone regeneration. > Lipid rafts are specific microdomains in the plasma membrane that contain high levels of sphingomyelin (SM) and cholesterol and are considered important signaling platforms. 7 SM is one of the major sphingolipid types and accounts for approximately 85% of the total sphingolipid content and 10%-20% of the total phospholipid content in the cell membrane. 8 SM is generally distributed in the bone tissue, skin epidermis, and myelin sheath in nerve tissue. Abnormalities in SM may cause bone mineralization defects, including severe bone abnormalities, severe skeletal and dental mineralization defects, and epiphyseal dysplasia of the spine. 9 SM synthetase (SMS) plays an important role in SM synthesis by transferring the phosphatidyl head group of phosphatidylcholine to the primary hydroxyl group of ceramide (Cer). SMS exists as two isomers: SMS1 (also known as SGMS1) and SMS2 (also known as SGMS2).

[16] Transcriptional profiling of Hutchinson-Gilford progeria patients identifies primary target pathways of progerin

• Authors: Sandra Vidak, Sohyoung Kim, Tom Misteli
• Year: 2026
• Venue: Nucleus
• URL: https://www.semanticscholar.org/paper/4bd99b0875508364d8672b6da5a50d024d485a53
• DOI: 10.1080/19491034.2025.2611484
• PMID: 41489464
• PMCID: 12773485
• Summary: To probe the clinical relevance of previously implicated cellular pathways and to address the extent of gene expression heterogeneity between patients, transcriptomic analysis of a comprehensive set of HGPS patients finds misexpression of several cellular pathways, including multiple signaling pathways, the UPR and mesodermal cell fate specification.
• Evidence snippets:
• Snippet 1 (score: 0.401) > Oxidative stress represents another key pathogenic mechanism in HGPS, as impaired NRF2 activity or increased reactive oxygen species (ROS) levels are sufficient to recapitulate HGPSassociated phenotypes [17,32,60]. Collectively, these findings underscore the multifactorial nature of HGPS pathogenesis, implicating interconnected signaling cascades involved in inflammation, oxidative stress, proteostasis, and vascular remodeling. Reassuringly, our findings indicate that many of the major pathways that have been described to contribute to HGPS phenotypes in mouse and cellular disease models are also misregulated in progeria patients, and targeting these pathways may provide therapeutic avenues to mitigate disease severity and improve outcomes in HGPS. > Although individuals with HGPS typically exhibit a characteristic set of clinical features, such as craniofacial abnormalities, growth retardation, and cardiovascular complications, there is notable variability in the age of onset, severity, and progression of symptoms between patients [7,9]. At the cellular level, HGPS is associated with several hallmark abnormalities, including nuclear envelope defects, decreased expression of several nuclear proteins and epigenetic marks, mitochondrial dysfunction, and increased cellular senescence [1,11,30,31,61]. These cellular phenotypes also exhibit considerable variation between patients, possibly contributing to differences in clinical outcomes. Our results indicate that even though some degree of transcriptional heterogeneity between the individual patients exists, the majority of patients exhibit misregulation of a set of shared pathways, suggesting that these pathways are universal driver mechanisms in HGPS. Further work is needed to understand the molecular and genetic factors that underlie inter-individual variability in disease expression and progression. > A limitation of pathway analysis of HGPS patient samples is to distinguish the pathways which are directly targeted by the disease-causing progerin protein and the emergence of adaptive secondary response pathways during progression of the disease in patients during their lifetime. The same caveat applies to the use of cell-based models used in the study of HGPS disease mechanisms.

[17] Channelopathies

• Authors: June-Bum Kim
• Year: 2014
• Venue: Korean Journal of Pediatrics
• URL: https://www.semanticscholar.org/paper/34ce44d327f3dec39d66a1b56c710345db1f08ce
• DOI: 10.3345/kjp.2014.57.1.1
• PMID: 24578711
• PMCID: 3935107
• Citations: 136
• Influential citations: 3
• Summary: This review provides a brief overview and update of channelopathies, with a focus on recent advances in the pathophysiological mechanisms that may help clinicians better understand, diagnose, and develop treatments for these diseases.
• Evidence snippets:
• Snippet 1 (score: 0.401) > Hereditary motor and sensory neuropathy type IIC (also known as Charcot-Marie-Tooth disease type 2C), congenital distal spinal muscular atrophy, and scapuloperoneal spinal muscular atrophy are allelic disorders with overlapping phenotypes derived from mutations in a TRP cation channel gene, TRPV4. TRPV4 mutations have also been implicated in skeletal dysplasias that include meta tropic dysplasia, spondylometaphyseal dysplasia Kozlowski type, brachyolmia type 3, spondyloepiphyseal dysplasia Maroteaux type, familial digital arthropathy with brachydactyly, and paras tremmatic dysplasia 36) . TRP channels are non-selective cation channels that play critical roles in intracellular signaling and homeostasis of calcium and/or magnesium. Mammalian TRP channels belong to six subfamilies: TRP canonical (TRPC), TRP vanilloid (TRPV), TRP melastatin (TRPM), TRP ankyrin (TRPA), TRP polycystin (TRPP), and TRP mucolipin (TRPML). Mutations of the TRPML1 channel (also termed mucolipin 1), a member of the TRPML subfamily, cause mucolipidosis type IV, an autosomal-recessive neurodegenerative lysosomal storage disorder that is characterized by severe psychomotor delay and visual impairment worsening over time. Loss-of-function mutations of TRPML1 channels have been shown to disturb calcium permeability and lysosomal acidification in affected cells 37) , but the precise pathophysiological mechanism underlying the clinical manifestations of the mutations remains to be elucidated.

Notes

• This provider combines search_papers_by_relevance with snippet_search.
• No synthesis or second-stage model call is performed.

Target Disease

• Disease Name: Spondylometaphyseal Dysplasia, Kozlowski Type
• MONDO ID: Not available (Orphanet: 93314; OMIM: 184252)
• Category: Mendelian (Autosomal Dominant Skeletal Dysplasia)

1. Core Pathophysiology

Spondylometaphyseal dysplasia, Kozlowski type (SMDK) is a genetic skeletal disorder caused by pathogenic variants in the TRPV4 gene (www.orpha.net) (ojrd.biomedcentral.com). TRPV4 encodes the transient receptor potential cation channel subfamily V member 4 (TRPV4, HGNC:18083), a calcium-permeable ion channel that acts as a mechanosensor in cartilage and bone tissues (www.ncbi.nlm.nih.gov) (ojrd.biomedcentral.com). In normal physiology, TRPV4 channels are activated by mechanical stimuli, temperature, and osmotic changes, leading to controlled Ca^2+ influx (calcium ion, CHEBI:29108) that helps regulate chondrocyte function and cartilage homeostasis (www.ncbi.nlm.nih.gov) (ojrd.biomedcentral.com). In SMDK, TRPV4 mutations are typically gain-of-function, causing excessive or dysregulated Ca^2+ signaling in chondrocytes (ojrd.biomedcentral.com). This aberrant calcium influx perturbs downstream signaling pathways and cellular processes essential for endochondral bone development (www.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). As a result, growth plate cartilage fails to mature properly and endochondral ossification (bone formation from cartilage) is disrupted. Key findings from cellular models show that TRPV4 mutations alter BMP (bone morphogenetic protein) signaling and prevent normal chondrocyte hypertrophy, which is a crucial step in bone growth (pubmed.ncbi.nlm.nih.gov). In vitro, mutant TRPV4-expressing chondrocytes have suppressed hypertrophic differentiation and diminished response to mechanical load (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Together, these molecular derangements lead to defective cartilage matrix organization, impaired growth plate function, and skeletal dysplasia in SMDK.

Notably, while most TRPV4-related skeletal dysplasias result from gain-of-function effects, a recent study identified an atypical loss-of-function TRPV4 variant (p.W785S) in an SMDK patient (ojrd.biomedcentral.com). This variant showed reduced calcium influx and channel activity, a mechanism deviating from the usual TRPV4 hyperactivation paradigm (ojrd.biomedcentral.com). The loss of TRPV4 function was associated with a relatively milder SMDK phenotype (ojrd.biomedcentral.com), suggesting that both excessive and insufficient TRPV4 activity can disrupt cartilage homeostasis. In summary, the core pathophysiology of SMDK is dominated by abnormal TRPV4 channel activity in developing cartilage, leading to altered intracellular calcium signaling, downstream activation of pathological pathways (e.g. calcium-sensitive proteases/kinases and transcription factors), and failure of normal skeletal development (www.ncbi.nlm.nih.gov) (ojrd.biomedcentral.com).

2. Key Molecular Players

• Gene/Protein: TRPV4 – The causative gene in SMDK encodes the TRPV4 ion channel (a Ca^2+-permeable, non-selective cation channel) (www.ncbi.nlm.nih.gov). TRPV4 is highly expressed in chondrocytes (CL:0000138, cartilage cells) of the growth plate and in osteoblastic cells, where it senses mechanical cues and contributes to cartilage and bone integrity (ojrd.biomedcentral.com). Mutant TRPV4 proteins (due to missense variants) can have increased basal activity or altered gating (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This leads to constitutive calcium influx and aberrant activation of signaling cascades within cartilage cells. In chondrocytes, TRPV4 gain-of-function mutations provoke upregulation of factors like follistatin (FST), a BMP antagonist, linking TRPV4 hyperactivity to suppression of BMP signaling (pmc.ncbi.nlm.nih.gov). Elevated FST inhibits BMP-induced maturation of chondrocytes, contributing to delayed or stunted ossification (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Conversely, TRPV4 loss-of-function can mean insufficient mechanotransduction, potentially impairing the normal anabolic responses to mechanical stress in cartilage (ojrd.biomedcentral.com).

• Molecular Pathways: The pathogenic TRPV4 variants perturb multiple pathways. Calcium signaling pathways are central – excessive Ca^2+ entry can activate calcium-dependent enzymes (e.g. calpains and CaMKII) and transcription factors (e.g. NF-κB, NFAT) that alter gene expression in chondrocytes (www.ncbi.nlm.nih.gov). One downstream effect is the disruption of TGF-β/BMP signaling in the growth plate: studies show mutant TRPV4 blunts the pro-hypertrophic signals of BMP4 in chondrocytes, blocking normal hypertrophic differentiation (pubmed.ncbi.nlm.nih.gov). Retinoic acid signaling has also been implicated, as severe TRPV4 mutations (e.g. p.T89I) were linked to dysregulated retinoic acid pathway genes in cartilage cells (pmc.ncbi.nlm.nih.gov). Furthermore, TRPV4 interacts with mechanotransduction pathways; it works alongside channels like PIEZO1 to sense mechanical load. Normally, TRPV4 activation under physiological strain promotes chondrogenesis, whereas hyperactivation (or lack of modulation) leads to cellular stress or altered differentiation (pubmed.ncbi.nlm.nih.gov). In SMDK, mechanosensitive signaling is impaired – mutant chondrocytes show diminished mechano-responsiveness, failing to upregulate key extracellular matrix and ossification genes when mechanical stimuli occur (pmc.ncbi.nlm.nih.gov). This contributes to weak cartilage structure and abnormal bone modeling.

• Chemical/Metabolic Factors: Calcium ions (Ca^2+) are the key second messenger in TRPV4-mediated signaling (ojrd.biomedcentral.com). Abnormal Ca^2+ homeostasis in SMDK chondrocytes can activate catabolic processes or inhibit normal anabolic pathways. Related metabolites include those in the cartilage extracellular matrix (e.g. glycosaminoglycans, collagens) which are downstream of mechanotransduction. For instance, changes in type II collagen (COL2A1) and proteoglycan production have been observed with TRPV4 dysregulation (pmc.ncbi.nlm.nih.gov), reflecting matrix abnormalities. No specific toxic metabolites are known in SMDK, but altered expression of oxidative stress enzymes (e.g. catalase, glutathione S-transferase) has been noted, suggesting a possible imbalance in redox homeostasis in mutant chondrocytes (pubmed.ncbi.nlm.nih.gov). There are currently no approved drug therapies targeted at TRPV4 for SMDK, though experimental TRPV4 inhibitors (such as GSK205 or GSK2193874) can normalize Ca^2+ influx in cell models (pmc.ncbi.nlm.nih.gov). In a TRPV4 knock-in mouse model of neuropathy, a TRPV4 antagonist rescued the phenotype (www.ncbi.nlm.nih.gov), raising the prospect that pharmacological TRPV4 blockade might ameliorate skeletal pathology as well.

• Cell Types: The primary affected cells are growth plate chondrocytes (hypertrophic and proliferative chondrocytes in the metaphysis of long bones, UBERON:0002495) and articular chondrocytes in spinal vertebrae. These cartilage cells bear the brunt of TRPV4 dysfunction, leading to defective cartilage templates for bone. Osteoblasts and osteocytes (bone-forming cells) may secondarily be affected due to aberrant signaling from cartilage or direct TRPV4 expression in these cells. Indeed, TRPV4 is expressed in osteoblasts and osteocytes, contributing to bone mechanosensitivity (www.ncbi.nlm.nih.gov). Mutations might alter osteoblastic activity or mineralization indirectly. There is also evidence that neurons (particularly peripheral motor and sensory neurons) express TRPV4; in some TRPV4 mutations, patients demonstrate both skeletal dysplasia and peripheral neuropathy (pmc.ncbi.nlm.nih.gov). However, classic SMDK usually manifests with skeletal findings alone, indicating a bone-centric effect of the particular TRPV4 variants involved.

• Tissues/Anatomical Sites: SMDK primarily involves the spine (vertebrae) and the metaphyses of long bones. The vertebral column (UBERON:0001132) shows platyspondyly (flattened vertebral bodies) and abnormal curvature. The growth plates at the ends of bones (in femora, tibiae, etc.) exhibit widened, irregular metaphyses due to disorganized chondrocyte columns (ojrd.biomedcentral.com). The pelvis (hip bones) is also affected (often with short ilia and flattened acetabular roofs), and sometimes the ribs and sternum (leading to chest wall deformity). These skeletal sites are where endochondral ossification is most active, aligning with TRPV4’s role in those regions. Other organ systems are largely unaffected (intelligence is normal and internal organs develop normally), consistent with TRPV4’s tissue-specific impact in this syndrome (www.orpha.net).

3. Disrupted Biological Processes (GO Terms)

The pathogenic sequence in SMDK can be mapped to several disrupted Gene Ontology (GO) biological processes: - Endochondral Ossification (GO:0001958): This is the process of bone formation from a cartilage template. In SMDK, endochondral ossification is fundamentally impaired – mutant chondrocytes fail to properly undergo hypertrophy and mineralization (pubmed.ncbi.nlm.nih.gov), causing delayed ossification and bone growth failure. Radiographically, this appears as metaphyseal dysplasia and delayed skeletal maturation (pmc.ncbi.nlm.nih.gov).
- Chondrocyte Differentiation (GO:0002062) and Hypertrophy: TRPV4 mutations blunt the normal progression of chondrocytes from proliferative to hypertrophic states (pubmed.ncbi.nlm.nih.gov). Hypertrophic chondrocyte differentiation – normally driven by BMP and Indian hedgehog signaling – is suppressed, as evidenced by reduced expression of hypertrophy markers (e.g. COL10A1, RUNX2) in mutant cells (pubmed.ncbi.nlm.nih.gov). This leads to persistence of immature cartilage and failure to transition to bone.
- Mechanotransduction (GO:0071259) and Mechanosensory Response: TRPV4 is a key mediator of mechanical stimulus signaling in cartilage. In healthy chondrocytes, moderate mechanical loading opens TRPV4 channels, triggering anabolic responses (matrix production) (pubmed.ncbi.nlm.nih.gov). In SMDK, mechanotransduction is dysregulated – the constitutively active channel yields a constant signal that desensitizes cells to actual mechanical cues (pmc.ncbi.nlm.nih.gov). Mutant chondrocytes show diminished mechanoresponsiveness, failing to upregulate genes in response to load (pmc.ncbi.nlm.nih.gov). This aberration in signal transduction (GO:0023052) contributes to abnormal joint and spine development (since cartilage does not adapt properly to growth forces).
- Calcium Ion Transport and Homeostasis (GO:0070588, GO:0055074): TRPV4 GOF mutations cause excessive calcium ion transmembrane transport into chondrocytes at inappropriate times (ojrd.biomedcentral.com). The disruption of calcium homeostasis triggers pathological cascades, as intracellular Ca^2+ regulates many processes. Calcium-activated proteases (like calpain) can degrade cytoskeletal and matrix proteins if overactivated (www.ncbi.nlm.nih.gov). Calcium-dependent signaling (e.g. calmodulin/CaMK pathways, calcineurin-NFAT signaling) is abnormally turned on, altering gene expression profiles in cartilage. For example, mutant chondrocytes show changed expression of HOX genes and antioxidant enzymes regulated by Ca^2+-sensitive pathways (pubmed.ncbi.nlm.nih.gov).
- Bone Morphogenetic Protein Signaling (GO:0030509): As noted, a specific downstream effect is BMP signaling suppression via upregulation of follistatin (an extracellular BMP inhibitor) (pmc.ncbi.nlm.nih.gov). Normally, BMPs (e.g. BMP2, BMP4) promote cartilage maturation and bone formation. In SMDK chondrocytes, pathogenic TRPV4 activation increases follistatin (FST) expression, which binds BMPs and hinders their interactions with receptors (pmc.ncbi.nlm.nih.gov). Consequently, the GO process “positive regulation of chondrocyte differentiation” (GO:0032332) by BMP is turned into a negative outcome, contributing to unossified cartilage matrix.
- Extracellular Matrix Organization (GO:0030198): Mutant TRPV4 also perturbs cartilage matrix composition. Transcriptomic analyses of TRPV4-mutant chondrocytes reveal deregulation of genes for collagens (COL2A1, COL9A1) and other matrix components (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Processes like cartilage extracellular matrix organization and collagen fibril assembly are affected. This explains the histopathology of SMDK cartilage, which shows areas of disorganized matrix and metaphyseal cartilage widening (ojrd.biomedcentral.com). The growth plate cartilage may have abnormal proteoglycan distribution and reduced tensile strength, aligning with the GO term “abnormal cartilage morphology” (as captured by phenotype rather than GO).

Other processes that may be involved include osteoblast differentiation (GO:0001649) – since impaired signals from cartilage can secondarily affect bone formation – and ion homeostasis (GO:0050801) due to chronic calcium imbalance in cells. Inflammation is not a known primary process in SMDK (there is no overt inflammatory component), but recent data suggest stress-response pathways (like oxidative stress response) are triggered in chondrocytes dealing with chronic calcium overload (pubmed.ncbi.nlm.nih.gov).

4. Key Cellular Components (Subcellular Localization)

Pathogenic mechanisms in SMDK are tied to specific cellular compartments where TRPV4 operates: - Plasma Membrane (GO:0005886): TRPV4 is predominantly a plasma membrane protein in chondrocytes (www.ncbi.nlm.nih.gov). It forms a cation channel complex in the cell membrane, allowing Ca^2+ influx from the extracellular space. The channel’s abnormal activity directly at the membrane causes altered membrane currents and calcium entry (ojrd.biomedcentral.com). Many downstream events (activation of membrane-localized enzymes, receptors, etc.) initiate here. For instance, calpain proteases associated with the cytoplasmic face of the membrane could be activated by influx of Ca^2+. TRPV4 may also interact with other membrane proteins (e.g. integrins or other mechanoreceptors) in forming a mechanosensory complex. - Primary Cilium (GO:0036064): Chondrocytes have a solitary primary cilium, an organelle important for mechanotransduction. Studies indicate that TRPV4’s mechanosensitive function in cartilage partly involves the primary cilium structure (pubmed.ncbi.nlm.nih.gov). The TRPV4 channel localizes to the ciliary membrane in some cells, and ciliary bending during mechanical stress can activate TRPV4. Integrity of the cilium is required for proper TRPV4 signaling in cartilage (pubmed.ncbi.nlm.nih.gov). If TRPV4 is overactive, it might also disturb ciliary signaling hubs (which include calcium-dependent signaling pathways). Thus, the ciliary compartment is a key locale for the mechanosignaling defects in SMDK, linking to pathways like Hedgehog signaling that are coordinated in cilia (though direct evidence of TRPV4-Hedgehog interplay in SMDK is still emerging). - Endoplasmic Reticulum (GO:0005783) and Calcium Stores: Abnormal plasma-membrane Ca^2+ influx can secondarily affect the ER, which serves as an internal Ca^2+ store. Sustained TRPV4 activity might alter ER calcium levels and trigger unfolded protein response (GO:0030968) or ER stress if homeostasis is disrupted (this is speculative but suggested by the presence of cellular stress markers in mutant chondrocytes (pubmed.ncbi.nlm.nih.gov)). - Cytoskeleton (GO:0005856): The cytoskeleton of chondrocytes (including actin filaments and microtubules) is sensitive to calcium and mechanical signals. Dysregulated TRPV4 activity can cause cytoskeletal remodeling defects (www.ncbi.nlm.nih.gov). Calcium-dependent cytoskeletal regulators (e.g. gelsolin, troponin, calmodulin) may be aberrantly activated. This could explain morphological changes in SMDK chondrocytes and contribute to weak structural integrity of cartilage. Indeed, histology often shows chondrocytes that are irregularly arranged, suggesting cytoskeletal or polarity changes. - Extracellular Matrix (GO:0031012): While not a “cellular component” of the cell, the cartilage extracellular matrix is a crucial environment where TRPV4’s effects manifest. TRPV4-mediated signaling influences the deposition of collagen and proteoglycans outside the cell. In SMDK, the extracellular matrix of cartilage is abnormal, with evidence of deficient mineral deposition and persistence of cartilage in zones that should ossify (pmc.ncbi.nlm.nih.gov). The growth plate ECM is widened (metaphyseal widening on X-ray) due to accumulation of cartilage that fails to turn into bone (ojrd.biomedcentral.com). This essentially external compartment reflects the internal cellular dysfunction.

5. Disease Progression

Initiation: The disease process of SMDK is initiated in utero by the presence of a heterozygous TRPV4 mutation at conception. Even before birth, the developing skeleton’s chondrocytes are experiencing abnormal calcium signaling. However, many skeletal changes are subtle during embryogenesis and at birth the phenotype may not be obvious or may be mistaken for mild shortening. Neonates with SMDK often have near-normal lengths, but the groundwork for dysplasia is laid in the growth plates.

Early Childhood: The disorder typically becomes evident in the postnatal period, especially as growth accelerates in infancy and toddlerhood. By the time the child begins to walk (around 1–2 years), growth delays and skeletal deformities start to manifest (pmc.ncbi.nlm.nih.gov). The spine begins to show abnormal curvature (progressive kyphoscoliosis), and a waddling gait may be noticed due to hip and femoral deformities (pmc.ncbi.nlm.nih.gov). During this stage, pathological changes involve progressive deformity of vertebrae and long bones – the vertebral bodies become flattened (platyspondyly) as they grow, and metaphyses enlarge and flare abnormally. Microscopically, growth plate disorganization becomes more pronounced: columns of chondrocytes are irregular, and there's delayed transition from cartilage to bone. Clinically, parents may note the child’s short trunk and protuberant abdomen (due to lumbar lordosis or spinal curvature).

Late Childhood to Adolescence: The disease progresses with worsening spinal deformity and short stature. The kyphoscoliosis in SMDK is often progressive, meaning curvature increases as the child grows (pmc.ncbi.nlm.nih.gov). It may require bracing or surgical interventions (e.g. spinal fusion) during later childhood to prevent neurologic complications. Long bone bowing (genu varum, or bow-legs) becomes more apparent once weight-bearing increases; knee and ankle alignment issues can emerge. During this phase, secondary ossification centers (like the carpal bones) show delayed maturation – for example, carpal bone ossification is markedly delayed or remains incomplete even by later childhood (pmc.ncbi.nlm.nih.gov). This indicates the persistence of cartilage due to the ossification defect. Growth velocity remains low, and by puberty, the adult height is significantly below average (dwarfism, especially of the short-trunk type). Importantly, disproportion becomes clear: the limbs might be closer to normal length compared to the very short spine, characteristic of short-trunk dwarfism.

Adulthood: Once growth ceases, the active progression of deformities slows, but the residual skeletal abnormalities cause lifelong issues. Adults with SMDK have short stature (often under 5 feet) and chronic orthopedic problems. Spinal deformity can lead to chronic back pain or early degenerative changes. Joint degeneration (e.g. early osteoarthritis in hips or spine) may occur due to the abnormal biomechanics. A known risk in SMDK and related TRPV4 dysplasias is cervical spine instability: odontoid (dens) hypoplasia in the cervical vertebrae can predispose to atlantoaxial instability and compressive myelopathy (pubmed.ncbi.nlm.nih.gov). Indeed, a case report described a 9-year-old SMDK patient developing spinal cord compression due to the skeletal changes (pubmed.ncbi.nlm.nih.gov). Thus, neurologic complications can arise insidiously in later stages if bony stenosis or instability is present. Throughout adulthood, respiratory function might be mildly affected by severe kyphoscoliosis (restrictive pulmonary mechanics), and individuals might experience chronic pain or mobility limitations. There is no evidence that SMDK shortens lifespan dramatically, but quality of life can be impacted by orthopedic issues. The disease does not have distinct “remission” or “relapse” phases since it is a developmental anomaly; rather, it is a continuous developmental progression that plateaus after growth completion. Management is supportive (spinal surgeries, physical therapy), aimed at addressing the consequences of the progression rather than altering the underlying molecular pathology (which is currently irreversible). Emerging research into TRPV4 inhibitors or gene therapies may in the future offer ways to slow or modify disease progression at the molecular level, but these are not yet in practice.

6. Phenotypic Manifestations

SMDK presents a recognizable cluster of clinical and radiological phenotypes caused by the underlying pathophysiology. Key phenotypic features include:

• Disproportionate Short Stature (Short-Trunk Dwarfism): Affected individuals have a markedly shortened torso with relatively slightly shorter or average-length limbs (ojrd.biomedcentral.com). This reflects predominant spine involvement. Postnatal growth retardation is evident, with length falling off the growth curve in early childhood. Final adult height is often far below percentile (<120 cm in severe cases). This phenotype stems from impaired vertebral growth (platyspondyly) and compromised growth plate function in the spine. Human Phenotype Ontology (HPO): Short trunk (HP:0003521) and short stature (HP:0004322).

• Kyphoscoliosis: Nearly all reported SMDK cases develop a prominent curvature of the spine, with both kyphosis (forward curvature) and scoliosis (lateral curvature) (pmc.ncbi.nlm.nih.gov). The kyphoscoliosis (HP:0002751) is progressive and often severe, leading to a hunched back and sideways curvature visible on exam. This arises from the structural weakness of the platyspondylic vertebrae – the vertebral bodies are flat and cannot maintain normal alignment under mechanical load. Additionally, ligamentous laxity around the spine may contribute. The kyphoscoliosis correlates with the underlying vertebral platyspondyly (HP:0000926) and abnormal vertebral development due to TRPV4-mediated cartilage defects.

• Platyspondyly: X-rays show flattened vertebral bodies (platyspondyly) throughout the spine (pmc.ncbi.nlm.nih.gov). The vertebrae often have a characteristic "open staircase" appearance on lateral view (pmc.ncbi.nlm.nih.gov). This radiologic phenotype directly results from poor endochondral ossification in the vertebral growth plates, causing reduced vertebral height. Platyspondyly contributes to both the short trunk and spinal curvature. It is considered a hallmark radiographic sign in SMDK and related TRPV4 dysplasias.

• Metaphyseal Irregularities and Widening: The metaphyses (near the growth plates) of long bones, such as the femur and tibia, are abnormally widened and irregular (ojrd.biomedcentral.com). For example, the femoral neck metaphysis can appear short and broad. This reflects the accumulation of cartilaginous tissue that has not ossified properly. Clinically, this may correspond to enlarged joints – knees and ankles may appear broadened or swollen due to flaring of bone ends (ojrd.biomedcentral.com). Hips show short, square iliac bones and a shallow acetabulum (predisposing to hip dysplasia). These metaphyseal changes cause mechanical axis deviations, such as genu varum (bow-legged stance, HP:0002970), because the knees angle outward when the distal femur and proximal tibia are shaped abnormally.

• Chest Wall Deformity: Many individuals have pectus carinatum (pigeon chest, HP:0000768) – a protrusion of the sternum (pmc.ncbi.nlm.nih.gov). The ribs may be flared. This is due to abnormal costal cartilage growth at the sternocostal junctions (also formed by endochondral ossification). While not disabling, it is a visible phenotype that often accompanies short-trunk dwarfism syndromes. It indicates that TRPV4 mutation affects cartilage not only in the spine and long bones but also in the thoracic cage.

• Odontoid Hypoplasia: The odontoid process (dens) of the second cervical vertebra is frequently underdeveloped (pmc.ncbi.nlm.nih.gov). This atlantoaxial instability risk is a subtle but critical phenotype because it can lead to spinal cord compression. Odontoid hypoplasia is thought to result from abnormal ossification at the synchondrosis of C2. Clinically, it may be asymptomatic or present as neck pain or neurologic signs if subluxation occurs. Careful cervical imaging is required in SMDK to detect this, given its importance for anesthesia and surgical planning.

• Joint Laxity and Waddling Gait: Some patients exhibit hypermobile joints or ligamentous laxity, notably in the spine (contributing to scoliosis) and perhaps hands. Coupled with hip dysplasia and metaphyseal deformities, children often have a waddling gait (a side-to-side gait) when they start walking (pmc.ncbi.nlm.nih.gov). The gait abnormality is a functional manifestation of hip and femoral metaphyseal involvement. Enlarged knee joints and bowing can also alter gait mechanics.

• Delayed Skeletal Maturation: As mentioned, carpal ossification delay is characteristic (pmc.ncbi.nlm.nih.gov). At an age when multiple carpal bones should be ossified, SMDK patients have few if any ossification centers in the wrists. This is a radiographic phenotype highlighting generalized delay in endochondral bone formation. Dental development is usually normal (since tooth formation is not endochondral), and there are no major extraskeletal malformations.

Despite the skeletal abnormalities, it is important to note that intellect and organ function are normal in SMDK (www.orpha.net). This distinguishes purely skeletal dysplasias from metabolic or syndromic conditions. The phenotypes are largely confined to the bones and joints: there is no evidence of immune deficiency, no visceral malformations, and no primary neurological degeneration (unless secondary to skeletal issues).

Overall, the clinical phenotype of SMDK can be directly traced to the underlying molecular pathology in cartilage. Short stature and spinal deformity result from dysfunctional vertebral growth plates; bone shape abnormalities (metaphyseal flaring, bowing) arise from altered growth plate architecture in long bones; and features like pectus carinatum reflect anomalous cartilage growth in the rib cage. Each phenotypic feature underscores a facet of the disease’s pathophysiology – namely, that proper skeletal morphogenesis requires finely tuned TRPV4-mediated signaling, and when this tuning is lost, the result is a cascade of growth disturbances manifesting as Spondylometaphyseal Dysplasia, Kozlowski type.

References (Evidence)

• Krakow D. et al. (2009). Mutations in TRPV4 produce SMD Kozlowski type and metatropic dysplasia – Am. J. Hum. Genet. 84(3):307-15. PMID: 19232556 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Identified TRPV4 missense mutations as cause of SMDK; established the TRPV4 dysplasia spectrum.
• Orphanet (2009). SMD Kozlowski type – Disease Summary (www.orpha.net). Autosomal dominant skeletal dysplasia caused by mutation in TRPV4.
• GeneReviews (2023). Autosomal Dominant TRPV4 Disorders – NCBI Bookshelf. PMID: 20301403 (www.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov). Overview of TRPV4 channelopathies; notes gain-of-function mechanism and calcium-related downstream effects.
• Wang H. et al. (2025). A novel TRPV4 variant in SMD Kozlowski type (loss-of-function mechanism) – Orphanet J. Rare Dis. 20:575. PMID: 36588071 (ojrd.biomedcentral.com) (ojrd.biomedcentral.com). Reported first loss-of-function TRPV4 mutation in SMDK, indicating milder phenotype and expanding the pathogenic mechanism.
• Dicks A.R. et al. (2023). TRPV4 mutations suppress chondrocyte hypertrophy – eLife 12:e71154. PMID: 36810131 (pubmed.ncbi.nlm.nih.gov). Showed that TRPV4 V620I and T89I mutations alter Ca^2+ signaling, upend BMP4-induced hypertrophy, and change gene expression in human iPSC-derived chondrocytes.
• Leddy H.A. et al. (2014). Follistatin in chondrocytes links TRPV4 and skeletal malformations – FASEB J. 28(6):2525-37. PMID: 24577120 (pmc.ncbi.nlm.nih.gov). Demonstrated that activated TRPV4 upregulates FST (follistatin), which inhibits BMP signaling and chondrocyte maturation.
• Combined Phenotype Case – Faye E. et al. (2018). SMD Kozlowski and Charcot-Marie-Tooth 2C due to TRPV4 variant, Molecular Syndromology 10(3):154–160. PMID: 30796705 (pmc.ncbi.nlm.nih.gov). Example of TRPV4 mutation affecting both skeleton and peripheral nerves.
• Compressive Myelopathy in SMDK – Sahu P. et al. (2021). Case Report: TRPV4 SMD Kozlowski causing cervical myelopathy, World Neurosurgery 151:56-60. PMID: 33453399 (pubmed.ncbi.nlm.nih.gov). Highlights spinal cord compression from cervical spine abnormalities in SMDK.